Abstract INTRODUCTION We compared the association between mild behavioral impairment (MBI) and first‐ versus second‐generation tau‐positron emission tomography (PET) tracers in preclinical and prodromal Alzheimer's disease (AD). METHODS We assessed 110 individuals with head‐to‐head [18F]MK6240 and [18F]Flortaucipir tau...
I. Bizzi, Arthur C. Macedo, Lydia Trudel et al.· Alzheimer's & Dementia· 0 citations
It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...
B. Bellaver, G. Povala, P. C. L. Ferreira et al.· Molecular Neurodegeneration· 0 citations
Conventional phosphorylated tau (p‐tau)217 reliably identifies amyloid positron emission tomography (PET) positivity, but its ability to capture the full Aβ continuum is limited.
Lydia Trudel, J. Therriault, Arthur C. Macedo et al.· Alzheimer's & Dementia· 0 citations
Across regions and networks, SEOT performed similarly or better than tau load in predicting metabolic dysfunction and may improve diagnostic characterisation and prediction of cognitive impairment beyond [18F]FDG-PET.
Arthur C. Macedo, Lydia Trudel, S. A. Hosseini et al.· EBioMedicine· 1 citation
In low- and middle-income countries, Alzheimer’s disease (AD) constitutes a growing public health burden. However, AD biomarkers research remains underrepresented in African populations. This study assesses core biomarkers of AD and their relevance in the African context as potential aid in clinical diagnosis. Nigerian...
T. Akinyemi, I. Pola, K. Tan et al.· npj Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.